Maintenance Therapy of Levonorgestrel-releasing Intrauterine System (LNG-IUS) to Prevent the Recurrence of Symptomatic Endometriosis After Conservative Surgery

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2010 by Taipei Veterans General Hospital,Taiwan.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Taipei Veterans General Hospital,Taiwan
ClinicalTrials.gov Identifier:
NCT01125488
First received: April 26, 2010
Last updated: June 6, 2010
Last verified: June 2010
  Purpose

The recurrence rates of endometriosis reported in women 5 years after therapy with gonadotropin releasing hormone (GnRH) agonist were 74% for severe disease . No strategies to prevent the recurrence of endometriosis have been uniformly successful. Local progesterone treatment of endometriosis-associated dysmenorrhea with a levonorgestrel-releasing intrauterine system (LNG-IUS) for 12 months has resulted in a significant reduction in dysmenorrhea, pelvic pain and dyspareunia; a high degree of patient satisfaction; and a significant reduction in the volume of rectovaginal endometriotic nodules. LNG-IUS may become a more important option if a long-term medical suppression of endometriosis.

Based on literature review, I hypothesized that maintenance therapy of LNG-IUS in conjunction with the GnRH agonist could lower the recurrence rates endometriosis after conservative surgery. We try to answer the question whether maintenance therapy of LNG-IUS in conjunction with the GnRH agonist could lower the recurrence rates and thus extend the symptom-free interval (menorrhagia and dysmenorrhea) as compared to GnRH agonist alone after conservative surgery in severe endometriosis cases.


Condition Intervention Phase
Endometriosis
Device: LNG-IUS
Drug: GnRH agonist (triptorelin)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Maintenance Therapy of LNG-IUS in Conjunction With the GnRH Agonist to Prevent the Recurrence of Symptomatic Endometriosis After Conservative Surgery: A Prospective Randomized, Phase III Trial

Resource links provided by NLM:


Further study details as provided by Taipei Veterans General Hospital,Taiwan:

Primary Outcome Measures:
  • Recurrence rate of endometriosis [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    We will follow the patients for 2 years, after the end of GnRH agonist medical treatment. Number of Participants with recurrence as a Measure of the clinical efficacy of LNG-IUS maintenance therapy to prevent recurrence of endometriosis.


Secondary Outcome Measures:
  • the safety of LNG-IUS maintenance therapy to prevent recurrence of endometriosis. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
    Number of Participants with Adverse Events as a Measure of Safety and Tolerability.


Estimated Enrollment: 80
Study Start Date: March 2008
Estimated Study Completion Date: September 2010
Estimated Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LNG-IUS
LNG-IUS insertion during conservative surgery and GnRH agonist 6 doses.
Device: LNG-IUS
levonorgestrel-releasing intrauterine system (LNG-IUS) 52mg, duration 5 years
Other Name: mirena
Drug: GnRH agonist (triptorelin)
GnRH agonist (triptorelin 3.75 mg, sc q28day)
Active Comparator: GnRH agonist
The second group of patients receive GnRH agonist (triptorelin 3.75 mg, sc q28day) alone for 24 weeks.
Drug: GnRH agonist (triptorelin)
GnRH agonist (triptorelin 3.75 mg, sc q28day)

  Hide Detailed Description

Detailed Description:

Participants:

This post-surgical medical therapy trial will be undertaken among patients with moderate-severe symptomatic endometriosis (rASRM score >16, according to the American Society for Reproductive Medicine) or adenomyosis. Symptomatic endometriosis means menorrhagia or dysmenorrhea. All patients were surgically treated by a conservative approach (means preserve uterus and ovary).

Interventions:

In all patients, were prescribed 600 mg elemental Ca and 400 IU vitamin D (bid). The first group of patients receive LNG-IUS for 5 years and GnRH agonist (triptorelin 3.75 mg, sc q28day) for 24 weeks.

The second group of patients receive GnRH agonist (triptorelin 3.75 mg, sc q28day) alone for 24 weeks.

Patients were evaluated every month for 24 weeks, and at 3,6,9,12,15,18,21,24 months after the end of medical treatment.

Objectives and outcomes:

The main objective of this trial was to assess the clinical efficacy of LNG-IUS maintenance therapy to prevent recurrence of endometriosis. Thus the primary outcome measures of this trial is the recurrence rate of endometriosis.

During this trial, recurrence was defined as elevation of CA125 (6) or endometriosis lesion in sonography or symptoms suggesting endometriosis including menorrhagia or dysmenorrhea.

The pain score diary was based on the visual analogue scale in which patients recorded the occurrence an intensity of their pain daily. VAS consists of a subjective evaluation of the pain on a scale of 10 in which 0 is no pain and 10 the most severe pain (7).

Bleeding and menorrhagia were assessed as: 0= no bleeding; 1=spotting (light bleeding not requiring sanitary protection); 2=light bleeding (light bleeding requiring sanitary protection); 3=normal bleeding (bleeding similar to normal menstrual blood flow); and 4=heavy bleeding (bleeding exceeding normal menstrual blood flow). No bleeding was defined as 30 consecutive days with bleeding score 0 (8).

Randomization process:

Treatment allocation was performed in accordance with a computer-generated randomization sequence using numbered, sealed envelopes.

Evaluation of efficacy:

Sample size:

In calculating the sample size required, the primary assessment was the recurrence rates. A 31% recurrence rate after laparoscopic reproductive surgery and post-surgical treatment with a GnRH agonist has been reported (9). We expected a decrease in recurrence rates after laparoscopic conservative surgery and post-surgical treatment with GnRH agonist plus LNG-IUS. A difference of 25% between the allocated treatments was considered significant. To have a 90% chance of detecting such a difference at an overall significant level of 5%, 40 patients for each group were required.

Endpoints:

We will follow the patients for 2 years, after the end of GnRH agonist medical treatment. Thus the primary outcome measures of this trial is the recurrence rate of endometriosis.

The main objective of this trial was to assess the clinical efficacy of LNG-IUS maintenance therapy to prevent recurrence of endometriosis.

Statistical analysis plan:

The cumulative proportion of recurrences by plotting percent recurrences as a function of time was estimated by the method of Kaplan and Meier. The survival curves for each allocated treatment were compared with the log-rank test.

For quantitative variables with normal distribution, the parametric t-test was used; in the case of the other variables, the non-parametric Mann-Whitney test was applied. For qualitative variables, x2-test or Fisher's exact test were used. For dependent variables with numerical scores referring to long-term measurement, multivariate analysis of variance ( MANOVA) was used.

  Eligibility

Ages Eligible for Study:   20 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with moderate-severe symptomatic endometriosis (rASRM score >16) according to the American Society for Reproductive Medicine) or adenomyosis. Symptomatic endometriosis means menorrhagia or dysmenorrhea.
  • All patients were surgically treated by a conservative approach.
  • Levels of serum CA125 is higher than normal range.

Exclusion Criteria:

  • Further desire for child bearing in future 3 years.
  • Any treatment for endometriosis within the previous 2 months.
  • Any concomitant disease that can be an established cause of chronic pelvic pain and anemia (Thalassemia anemia, inflammation sequela, myoma , and pelvic congestion etc)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01125488

Contacts
Contact: Yi-Jen Chen, MD 886-2-28757566 chenyj@vghtpe.gov.tw
Contact: PH Wang, MD, PhD 886-2-28757566 phwang@vghtpe.gov.tw

Locations
Taiwan
Taipei Veterans Genreal Hospital Recruiting
Taipei, Taiwan, 11217
Contact: Yi-Jen Chen, MD. PhD     886 22 8757566     chenyj@vghtpe.gov.tw    
Principal Investigator: Yi-Jen Chen, MD            
Sponsors and Collaborators
Taipei Veterans General Hospital,Taiwan
Investigators
Principal Investigator: Yi-Jen Chen, MD Department OBS & GYN, Taipei Veterans General Hospital
  More Information

No publications provided

Responsible Party: Yi-Jen Chen MD, Department of Obstetrics & Gynecology,Taipei Veterans General Hospital,Taiwan
ClinicalTrials.gov Identifier: NCT01125488     History of Changes
Other Study ID Numbers: VGHIRB 97-04-03
Study First Received: April 26, 2010
Last Updated: June 6, 2010
Health Authority: Taiwan: Department of Health

Keywords provided by Taipei Veterans General Hospital,Taiwan:
Maintenance therapy
LNG-IUS
recurrence,endometriosis
Recurrence

Additional relevant MeSH terms:
Endometriosis
Recurrence
Genital Diseases, Female
Disease Attributes
Pathologic Processes
Levonorgestrel
Triptorelin
Deslorelin
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Pharmacologic Actions
Therapeutic Uses
Contraceptives, Oral, Synthetic
Contraceptives, Oral
Luteolytic Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on May 19, 2013